MDINDL,MDPNT,MDSTDT,DCMNAME,PT,MDEDDT,ATCCODE,ATCCLASS,REPEATSN,MDONG,STUDY,PRFTERM,CPEVENT,MDQSN2,DRUGCD,MDIND,MDQSN1,VISIT,PRODUCT,SUBEVE,INVSITE,MDVERB,MDQSNL2,MDQSNL1
LOCALLY ADVANCED,CISPLATIN,200805,MD_CANCER_MEDS,01-01,20080714,L01XA,Platinum compounds,2,N,MAXIS-08,Cisplatin,BASELINE,PD,412101001.0,L,C,1,Cisplatin,0,C008_408,CISPLATIN,PROGRESSIVE DISEASE,CHEMOTHERAPY
LOCALLY ADVANCED,IRINOTECAN,200805,MD_CANCER_MEDS,01-01,20080714,L01XX,Other antineoplastic agents,1,N,MAXIS-08,Irinotecan,BASELINE,PD,1280201001.0,L,C,1,Irinotecan,0,C008_408,IRINOTECAN,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,SORAFENIB,20070926,MD_CANCER_MEDS,01-02,20080619,L01XE,Protein kinase inhibitors,1,N,MAXIS-08,Sorafenib,BASELINE,PD,1632501001.0,M,C,1,Sorafenib,0,C008_408,SORAFENIB,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,ERLOTINIB,20080508,MD_CANCER_MEDS,01-02,20081030,L01XE,Protein kinase inhibitors,2,N,MAXIS-08,Erlotinib hydrochloride,BASELINE,PD,1611402002.0,M,C,1,Tarceva,0,C008_408,TARCEVA,PROGRESSIVE DISEASE,CHEMOTHERAPY
LOCALLY ADVANCED,DOXORUBICIN,200702,MD_CANCER_MEDS,01-03,200709,L01DB,Anthracyclines and related substances,2,N,MAXIS-08,Doxorubicin,BASELINE,PD,330901014.0,L,C,1,Adriamycin,0,C008_408,ADRIAMYCIN,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,DOXORUBICIN,20070323,MD_CANCER_MEDS,01-03,200705,L01DB,Anthracyclines and related substances,5,N,MAXIS-08,Doxorubicin,BASELINE,PD,330901014.0,M,C,1,Adriamycin,0,C008_408,ADRIAMYCIN,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,AVASTIN,200810,MD_CANCER_MEDS,01-03,200811,L01XC,Monoclonal antibodies,1,N,MAXIS-08,Bevacizumab,BASELINE,PD,1555201002.0,M,C,1,Avastin,1,C008_408,AVASTIN + IXEMPRA,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,IXEMPRA,200810,MD_CANCER_MEDS,01-03,200811,L01DC,Other cytotoxic antibiotics,1,N,MAXIS-08,Ixabepilone,BASELINE,PD,1676401003.0,M,C,1,Ixempra,1,C008_408,AVASTIN + IXEMPRA,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,XELODA,200807,MD_CANCER_MEDS,01-03,200809,L01BC,Pyrimidine analogues,2,N,MAXIS-08,Capecitabine,BASELINE,PD,1394301002.0,M,C,1,Xeloda,1,C008_408,AVASTIN + XELODA,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,AVASTIN,200807,MD_CANCER_MEDS,01-03,200809,L01XC,Monoclonal antibodies,2,N,MAXIS-08,Bevacizumab,BASELINE,PD,1555201002.0,M,C,1,Avastin,1,C008_408,AVASTIN + XELODA,PROGRESSIVE DISEASE,CHEMOTHERAPY
LOCALLY ADVANCED,CYCLOPHOSPHAMIDE,200702,MD_CANCER_MEDS,01-03,200709,L01AA,Nitrogen mustard analogues,1,N,MAXIS-08,Cyclophosphamide,BASELINE,PD,21101004.0,L,C,1,Cytoxan,0,C008_408,CYTOXAN,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,CYCLOPHOSPHAMIDE,20070323,MD_CANCER_MEDS,01-03,200706,L01AA,Nitrogen mustard analogues,4,N,MAXIS-08,Cyclophosphamide,BASELINE,PD,21101004.0,M,C,1,Cytoxan,0,C008_408,CYTOXAN,PROGRESSIVE DISEASE,CHEMOTHERAPY
LOCALLY ADVANCED,DOCETAXEL,200702,MD_CANCER_MEDS,01-03,200709,L01CD,Taxanes,3,N,MAXIS-08,Docetaxel,BASELINE,PD,1256101001.0,L,C,1,Docetaxel,0,C008_408,DOCETAXEL,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,VINORELBINE,200802,MD_CANCER_MEDS,01-03,200806,L01CA,Vinca alkaloids and analogues,6,N,MAXIS-08,Vinorelbine tartrate,BASELINE,PD,988503035.0,M,C,1,Vinorelbin,0,C008_408,VINORELBINE,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,,2005,MD_CANCER_MEDS,01-04,2006,L02BG,Aromatase inhibitors,2,N,MAXIS-08,Anastrozole,BASELINE,PD,1285001001.0,M,H,1,Anastrozole,0,C008_408,ANASTRAZOLE,PROGRESSIVE DISEASE,HORMONE THERAPY
METASTATIC DISEASE,BEVACIZUMAB,200605,MD_CANCER_MEDS,01-04,200608,L01XC,Monoclonal antibodies,4,N,MAXIS-08,Bevacizumab,BASELINE,,1555201001.0,M,C,1,Bevacizumab,0,C008_408,BEVACIZUMAB,NOT APPLICABLE(IF NEOADJUVANT OR ADJUVANT REGIMEN),CHEMOTHERAPY
METASTATIC DISEASE,CAPECITABINE,200610,MD_CANCER_MEDS,01-04,200705,L01BC,Pyrimidine analogues,1,N,MAXIS-08,Capecitabine,BASELINE,SD,1394301001.0,M,C,1,Capecitabine,1,C008_408,CAPECITABINE,STABLE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,COMBINATIONS OF ANTINEOPLASTIC AGENTS,200705,MD_CANCER_MEDS,01-04,200712,L01XY,Combinations of antineoplastic agents,2,N,MAXIS-08,Cyclophosphamide/Doxorubicin,BASELINE,SD,1460601002.0,M,C,1,Doxorubicin w/cyclophosphamide,1,C008_408,CYTOXAN/ADRIAMYCIN,STABLE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,DOCETAXEL,200605,MD_CANCER_MEDS,01-04,200608,L01CD,Taxanes,3,N,MAXIS-08,Docetaxel,BASELINE,,1256101001.0,M,C,1,Docetaxel,0,C008_408,DOCETAXEL,NOT APPLICABLE(IF NEOADJUVANT OR ADJUVANT REGIMEN),CHEMOTHERAPY
METASTATIC DISEASE,DOCETAXEL,200712,MD_CANCER_MEDS,01-04,200803,L01CD,Taxanes,3,N,MAXIS-08,Docetaxel,BASELINE,PD,1256101001.0,M,C,1,Docetaxel,1,C008_408,DOCETAXEL,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,LEUPRORELIN ACETATE,2005,MD_CANCER_MEDS,01-04,2005,L02AE,Gonadotropin releasing hormone analogues,5,N,MAXIS-08,Leuprorelin acetate,BASELINE,PD,726902002.0,M,H,1,Lupron,1,C008_408,LUPRON,PROGRESSIVE DISEASE,HORMONE THERAPY
METASTATIC DISEASE,TAMOXIFEN,200501,MD_CANCER_MEDS,01-04,200512,L02BA,Anti-estrogens,1,N,MAXIS-08,Tamoxifen,BASELINE,SD,388701001.0,M,C,1,Tamoxifen,0,C008_408,TAMOXIFEN,STABLE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,VINORELBINE,20080402,MD_CANCER_MEDS,01-04,20081217,L01CA,Vinca alkaloids and analogues,4,N,MAXIS-08,Vinorelbine tartrate,BASELINE,PD,988503035.0,M,C,1,Vinorelbin,1,C008_408,VINORELBINE,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,SORAFENIB,20080117,MD_CANCER_MEDS,01-05,20090421,L01XE,Protein kinase inhibitors,1,N,MAXIS-08,Sorafenib,BASELINE,PR,1632501001.0,M,C,1,Sorafenib,0,C008_408,SOREFINIB,PARTIAL RESPONSE,CHEMOTHERAPY
METASTATIC DISEASE,,20070927,MD_CANCER_MEDS,01-05,20071120,V10AA,Yttrium (90Y) compounds,2,N,MAXIS-08,Yttrium 90 Ibritumomab Tiuxetan,BASELINE,PD,5701001001.0,M,O,1,Yttrium 90 Ibritumomab Tiuxetan,0,C008_408,YTTRIUM 90,PROGRESSIVE DISEASE,OTHER
METASTATIC DISEASE,AZACITIDINE,200808,MD_CANCER_MEDS,01-06,200809,L01BC,Pyrimidine analogues,3,N,MAXIS-08,Azacitidine,BASELINE,PD,435501001.0,M,C,1,Azacitidine,3,C008_408,AZACYTIDINE,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,BICALUTAMIDE,200506,MD_CANCER_MEDS,01-06,200510,L02BB,Anti-androgens,1,N,MAXIS-08,Bicalutamide,BASELINE,PD,1271101001.0,M,H,1,Bicalutamide,1,C008_408,BICALUTAMIDE,PROGRESSIVE DISEASE,HORMONE THERAPY
METASTATIC DISEASE,BICALUTAMIDE,200602,MD_CANCER_MEDS,01-06,200606,L02BB,Anti-androgens,4,N,MAXIS-08,Bicalutamide,BASELINE,PD,1271101001.0,M,H,1,Bicalutamide,1,C008_408,BICALUTAMIDE,PROGRESSIVE DISEASE,HORMONE THERAPY
METASTATIC DISEASE,CAPECITABINE,200511,MD_CANCER_MEDS,01-06,200602,L01BC,Pyrimidine analogues,2,N,MAXIS-08,Capecitabine,BASELINE,PD,1394301001.0,M,C,1,Capecitabine,1,C008_408,CAPECITABINE,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,CARBOPLATIN,200710,MD_CANCER_MEDS,01-06,20080430,L01XA,Platinum compounds,5,N,MAXIS-08,Carboplatin,BASELINE,PD,740901001.0,M,C,1,Carboplatin,2,C008_408,CARBOPLATIN,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,CARBOPLATIN,200810,MD_CANCER_MEDS,01-06,200902,L01XA,Platinum compounds,6,N,MAXIS-08,Carboplatin,BASELINE,PD,740901001.0,M,C,1,Carboplatin,3,C008_408,CARBOPLATIN,PROGRESSIVE DISEASE,CHEMOTHERAPY
ADJUVANT,CYCLOPHOSPHAMIDE,200308,MD_CANCER_MEDS,01-06,200403,L01AA,Nitrogen mustard analogues,2,N,MAXIS-08,Cyclophosphamide,BASELINE,,21101001.0,A,C,1,Cyclophosphamide,0,C008_408,CYCLOPHOSPHAMIDE,NOT APPLICABLE(IF NEOADJUVANT OR ADJUVANT REGIMEN),CHEMOTHERAPY
METASTATIC DISEASE,CYCLOPHOSPHAMIDE,200709,MD_CANCER_MEDS,01-06,20080430,L01AA,Nitrogen mustard analogues,2,N,MAXIS-08,Cyclophosphamide,BASELINE,SD,21101001.0,M,C,1,Cyclophosphamide,2,C008_408,CYCLOPHOSPHAMIDE,STABLE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,DOXORUBICIN HYDROCHLORIDE,200812,MD_CANCER_MEDS,01-06,200902,L01DB,Anthracyclines and related substances,1,N,MAXIS-08,Pegylated liposomal doxorubicin hydrochloride,BASELINE,PD,330904003.0,M,C,1,Doxil,4,C008_408,DOXIL,PROGRESSIVE DISEASE,CHEMOTHERAPY
ADJUVANT,DOXORUBICIN,200308,MD_CANCER_MEDS,01-06,200403,L01DB,Anthracyclines and related substances,1,N,MAXIS-08,Doxorubicin,BASELINE,,330901001.0,A,C,1,Doxorubicin,0,C008_408,DOXORUBICIN,NOT APPLICABLE(IF NEOADJUVANT OR ADJUVANT REGIMEN),CHEMOTHERAPY
ADJUVANT,ETOPOSIDE,200404,MD_CANCER_MEDS,01-06,200410,L01CB,Podophyllotoxin derivatives,4,N,MAXIS-08,Etoposide,BASELINE,,511901001.0,A,C,1,Etoposide,0,C008_408,ETOPOSIDE,NOT APPLICABLE(IF NEOADJUVANT OR ADJUVANT REGIMEN),CHEMOTHERAPY
METASTATIC DISEASE,ETOPOSIDE,200709,MD_CANCER_MEDS,01-06,20080430,L01CB,Podophyllotoxin derivatives,3,N,MAXIS-08,Etoposide,BASELINE,SD,511901001.0,M,C,1,Etoposide,2,C008_408,ETOPOSIDE,STABLE DISEASE,CHEMOTHERAPY
ADJUVANT,IFOSFAMIDE,200404,MD_CANCER_MEDS,01-06,200410,L01AA,Nitrogen mustard analogues,5,N,MAXIS-08,Ifosfamide,BASELINE,,310701001.0,A,C,1,Ifosfamide,0,C008_408,IFOSFAMIDE,NOT APPLICABLE(IF NEOADJUVANT OR ADJUVANT REGIMEN),CHEMOTHERAPY
METASTATIC DISEASE,IRINOTECAN,200608,MD_CANCER_MEDS,01-06,200608,L01XX,Other antineoplastic agents,6,N,MAXIS-08,Irinotecan,BASELINE,PD,1280201001.0,M,C,1,Irinotecan,1,C008_408,IRINOTECAN,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,IRINOTECAN,200806,MD_CANCER_MEDS,01-06,200807,L01XX,Other antineoplastic agents,2,N,MAXIS-08,Irinotecan,BASELINE,PD,1280201001.0,M,C,1,Irinotecan,3,C008_408,IRINOTECAN,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,FOLINIC ACID,200902,MD_CANCER_MEDS,01-06,200905,V03AF,Detoxifying agents for antineoplastic treatment,5,N,MAXIS-08,Folinic acid,BASELINE,PD,566701002.0,M,C,1,Leucovorin,4,C008_408,LEUCOVORIN,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,,200506,MD_CANCER_MEDS,01-06,200510,L02AE,Gonadotropin releasing hormone analogues,6,N,MAXIS-08,Leuprorelin,BASELINE,PD,726901007.0,M,H,1,Leuprolide,0,C008_408,LUPROLIDE,PROGRESSIVE DISEASE,HORMONE THERAPY
METASTATIC DISEASE,,200602,MD_CANCER_MEDS,01-06,200606,L02AE,Gonadotropin releasing hormone analogues,3,N,MAXIS-08,Leuprorelin,BASELINE,PD,726901007.0,M,H,1,Leuprolide,1,C008_408,LUPROLIDE,PROGRESSIVE DISEASE,HORMONE THERAPY
METASTATIC DISEASE,METHOTREXATE,200902,MD_CANCER_MEDS,01-06,200905,L01BA,Folic acid analogues,4,N,MAXIS-08,Methotrexate,BASELINE,PD,113801001.0,M,C,1,Methotrexate,4,C008_408,METHOTREXATE,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,MITOXANTRONE,200710,MD_CANCER_MEDS,01-06,20080430,L01DB,Anthracyclines and related substances,4,N,MAXIS-08,Mitoxantrone,BASELINE,PD,661301001.0,M,C,1,Mitoxantrone,2,C008_408,MITOXANTRONE,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,PACLITAXEL,200810,MD_CANCER_MEDS,01-06,200902,L01CD,Taxanes,5,N,MAXIS-08,Paclitaxel,BASELINE,PD,1116001001.0,M,C,1,Paclitaxel,3,C008_408,PACLITAXEL,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,SORAFENIB,200812,MD_CANCER_MEDS,01-06,200902,L01XE,Protein kinase inhibitors,2,N,MAXIS-08,Sorafenib,BASELINE,PD,1632501001.0,M,C,1,Sorafenib,4,C008_408,SORAFENIB,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,SUNITINIB,200704,MD_CANCER_MEDS,01-06,200709,L01XE,Protein kinase inhibitors,1,N,MAXIS-08,Sunitinib,BASELINE,PD,5510201001.0,M,C,1,Sunitinib,2,C008_408,SUNITINIB,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,,200806,MD_CANCER_MEDS,01-06,200807,L01AX,Other alkylating agents,1,N,MAXIS-08,Temozolomide,BASELINE,PD,1304601001.0,M,C,1,Temozolomide,3,C008_408,TEMOZOLAMIDE,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,TEMOZOLOMIDE,200608,MD_CANCER_MEDS,01-06,200608,L01AX,Other alkylating agents,5,N,MAXIS-08,Temozolomide,BASELINE,PD,1304601001.0,M,C,1,Temozolomide,1,C008_408,TEMOZOLOMIDE,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,THIOTEPA,200710,MD_CANCER_MEDS,01-06,20080430,L01AC,Ethylene imines,6,N,MAXIS-08,Thiotepa,BASELINE,PD,53501001.0,M,C,1,Thiotepa,2,C008_408,THIOTEPA,PROGRESSIVE DISEASE,CHEMOTHERAPY
ADJUVANT,VINCRISTINE,200308,MD_CANCER_MEDS,01-06,200403,L01CA,Vinca alkaloids and analogues,3,N,MAXIS-08,Vincristine,BASELINE,,78801001.0,A,C,1,Vincristine,0,C008_408,VINCRISTINE,NOT APPLICABLE(IF NEOADJUVANT OR ADJUVANT REGIMEN),CHEMOTHERAPY
METASTATIC DISEASE,VINORELBINE,200902,MD_CANCER_MEDS,01-06,200905,L01CA,Vinca alkaloids and analogues,3,N,MAXIS-08,Vinorelbine tartrate,BASELINE,PD,988503035.0,M,C,1,Vinorelbin,4,C008_408,VINORELBINE,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,VORINOSTAT,200808,MD_CANCER_MEDS,01-06,200809,L01XX,Other antineoplastic agents,4,N,MAXIS-08,Vorinostat,BASELINE,PD,5707301001.0,M,C,1,Vorinostat,3,C008_408,VORINOSTAT,PROGRESSIVE DISEASE,CHEMOTHERAPY
LOCALLY ADVANCED,DOXORUBICIN,20080609,MD_CANCER_MEDS,01-07,20080609,L01DB,Anthracyclines and related substances,2,N,MAXIS-08,Doxorubicin,BASELINE,PD,330901014.0,L,O,1,Adriamycin,0,C008_408,ADRIAMYCIN TRANSARTERIAL CHEMO EMBOLIZATION,PROGRESSIVE DISEASE,OTHER
LOCALLY ADVANCED,,20060719,MD_CANCER_MEDS,01-07,20060719,,,4,N,MAXIS-08,,BASELINE,PD,,L,O,1,,0,C008_408,RIGHT AND LEFT HEPATIC LOBE RADIO FREQUENCY ABLATION,PROGRESSIVE DISEASE,OTHER
LOCALLY ADVANCED,SORAFENIB,20081104,MD_CANCER_MEDS,01-07,20090428,L01XE,Protein kinase inhibitors,1,N,MAXIS-08,Sorafenib,BASELINE,PD,1632501001.0,L,C,1,Sorafenib,0,C008_408,SOREFINIB,PROGRESSIVE DISEASE,CHEMOTHERAPY
LOCALLY ADVANCED,,20060412,MD_CANCER_MEDS,01-07,20060530,L01XX,Other antineoplastic agents,3,N,MAXIS-08,Antineoplastic agents,BASELINE,PD,90031501001.0,L,O,1,Antineoplastic agents,0,C008_408,UNKNOWN DRUG TRANSARTERIAL CHEMO EMBOLIZATION X2,PROGRESSIVE DISEASE,OTHER
METASTATIC DISEASE,FLUOROURACIL,20070322,MD_CANCER_MEDS,01-08,20070927,L01BC,Pyrimidine analogues,1,N,MAXIS-08,Fluorouracil,BASELINE,SD,98801001.0,M,C,1,Fluorouracil,0,C008_408,FLUOROURACIL,STABLE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,FLUOROURACIL,20090324,MD_CANCER_MEDS,01-08,20090407,L01BC,Pyrimidine analogues,4,N,MAXIS-08,Fluorouracil,BASELINE,PD,98801001.0,M,C,1,Fluorouracil,0,C008_408,FLUOROURACIL,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,GEMCITABINE,20080829,MD_CANCER_MEDS,01-08,20090212,L01BC,Pyrimidine analogues,3,N,MAXIS-08,Gemcitabine,BASELINE,SD,1215701001.0,M,C,1,Gemcitabine,0,C008_408,GEMCITABINE,STABLE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,FOLINIC ACID,20070322,MD_CANCER_MEDS,01-08,20070927,V03AF,Detoxifying agents for antineoplastic treatment,2,N,MAXIS-08,Folinic acid,BASELINE,SD,566701002.0,M,C,1,Leucovorin,0,C008_408,LEUCOVORIN,STABLE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,FOLINIC ACID,20090324,MD_CANCER_MEDS,01-08,20090407,V03AF,Detoxifying agents for antineoplastic treatment,5,N,MAXIS-08,Folinic acid,BASELINE,PD,566701002.0,M,C,1,Leucovorin,0,C008_408,LEUCOVORIN,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,OXALIPLATIN,20090324,MD_CANCER_MEDS,01-08,20090407,L01XA,Platinum compounds,6,N,MAXIS-08,Oxaliplatin,BASELINE,PD,1318801001.0,M,C,1,Oxaliplatin,0,C008_408,OXALIPLATIN,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,PEMETREXED,20090423,MD_CANCER_MEDS,01-09,20090603,L01BA,Folic acid analogues,2,N,MAXIS-08,Pemetrexed disodium,BASELINE,PD,1493902003.0,M,C,1,Alimta,1,C008_408,ALIMTA,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,BEVACIZUMAB,20081002,MD_CANCER_MEDS,01-09,20090317,L01XC,Monoclonal antibodies,3,N,MAXIS-08,Bevacizumab,BASELINE,SD,1555201002.0,M,C,1,Avastin,0,C008_408,AVASTIN,STABLE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,CISPLATIN,20090203,MD_CANCER_MEDS,01-09,20090317,L01XA,Platinum compounds,1,N,MAXIS-08,Cisplatin,BASELINE,PD,412101001.0,M,C,1,Cisplatin,1,C008_408,CISPLATIN,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,FLUOROURACIL,20080715,MD_CANCER_MEDS,01-09,20090317,L01BC,Pyrimidine analogues,2,N,MAXIS-08,Fluorouracil,BASELINE,SD,98801001.0,M,C,1,Fluorouracil,0,C008_408,FLUOROURACIL,STABLE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,GEMZAR,20080521,MD_CANCER_MEDS,01-09,20080703,L01BC,Pyrimidine analogues,1,N,MAXIS-08,Gemcitabine hydrochloride,BASELINE,PD,1215702002.0,M,C,1,Gemzar,0,C008_408,GEMZAR/TARCEVA,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,TARCEVA,20080521,MD_CANCER_MEDS,01-09,20080703,L01XE,Protein kinase inhibitors,1,N,MAXIS-08,Erlotinib hydrochloride,BASELINE,PD,1611402002.0,M,C,1,Tarceva,0,C008_408,GEMZAR/TARCEVA,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,,20090217,MD_CANCER_MEDS,01-09,20090317,L01XX,Other antineoplastic agents,6,N,MAXIS-08,Irinotecan,BASELINE,PD,1280201001.0,M,C,1,Irinotecan,0,C008_408,IRIHOTECAN,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,FOLINIC ACID,20080715,MD_CANCER_MEDS,01-09,20090317,V03AF,Detoxifying agents for antineoplastic treatment,5,N,MAXIS-08,Folinic acid,BASELINE,SD,566701002.0,M,C,1,Leucovorin,0,C008_408,LEUCOVORIN,STABLE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,OXALIPLATIN,20080715,MD_CANCER_MEDS,01-09,20081223,L01XA,Platinum compounds,4,N,MAXIS-08,Oxaliplatin,BASELINE,SD,1318801001.0,M,C,1,Oxaliplatin,0,C008_408,OXALIPLATIN,STABLE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,BEVACIZUMAB,200708,MD_CANCER_MEDS,01-10,200903,L01XC,Monoclonal antibodies,6,N,MAXIS-08,Bevacizumab,BASELINE,PR,1555201001.0,M,C,1,Bevacizumab,1,C008_408,BEVACIZUMAB,PARTIAL RESPONSE,CHEMOTHERAPY
METASTATIC DISEASE,CAPECITABINE,200304,MD_CANCER_MEDS,01-10,200310,L01BC,Pyrimidine analogues,4,N,MAXIS-08,Capecitabine,BASELINE,SD,1394301001.0,M,C,1,Capecitabine,0,C008_408,CAPECITABINE,STABLE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,CAPECITABINE,200410,MD_CANCER_MEDS,01-10,200606,L01BC,Pyrimidine analogues,6,N,MAXIS-08,Capecitabine,BASELINE,SD,1394301001.0,M,C,1,Capecitabine,0,C008_408,CAPECITABINE,STABLE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,CAPECITABINE,200810,MD_CANCER_MEDS,01-10,200903,L01BC,Pyrimidine analogues,1,N,MAXIS-08,Capecitabine,BASELINE,SD,1394301001.0,M,C,1,Capecitabine,2,C008_408,CAPECITABINE,STABLE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,CETUXIMAB,200410,MD_CANCER_MEDS,01-10,200606,L01XC,Monoclonal antibodies,2,N,MAXIS-08,Cetuximab,BASELINE,SD,1490501001.0,M,C,1,Cetuximab,1,C008_408,CETUXIMAB,STABLE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,FLUOROURACIL,200701,MD_CANCER_MEDS,01-10,200708,L01BC,Pyrimidine analogues,3,N,MAXIS-08,Floxuridine,BASELINE,SD,356401001.0,M,C,1,Floxuridine,1,C008_408,FLUORODEOXYURIDINE,STABLE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,FLUOROURACIL,20001130,MD_CANCER_MEDS,01-10,200102,L01BC,Pyrimidine analogues,2,N,MAXIS-08,Fluorouracil,BASELINE,PD,98801001.0,M,C,1,Fluorouracil,0,C008_408,FLUOROURACIL,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,FLUOROURACIL,200708,MD_CANCER_MEDS,01-10,200810,L01BC,Pyrimidine analogues,5,N,MAXIS-08,Fluorouracil,BASELINE,PR,98801001.0,M,C,1,Fluorouracil,1,C008_408,FLUOROURACIL,PARTIAL RESPONSE,CHEMOTHERAPY
METASTATIC DISEASE,IRINOTECAN,20001130,MD_CANCER_MEDS,01-10,200102,L01XX,Other antineoplastic agents,1,N,MAXIS-08,Irinotecan,BASELINE,PD,1280201001.0,M,C,1,Irinotecan,0,C008_408,IRINOTECAN,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,IRINOTECAN,200708,MD_CANCER_MEDS,01-10,200903,L01XX,Other antineoplastic agents,4,N,MAXIS-08,Irinotecan,BASELINE,PR,1280201001.0,M,C,1,Irinotecan,1,C008_408,IRINOTECAN,PARTIAL RESPONSE,CHEMOTHERAPY
METASTATIC DISEASE,FOLINIC ACID,20001130,MD_CANCER_MEDS,01-10,200102,V03AF,Detoxifying agents for antineoplastic treatment,3,N,MAXIS-08,Folinic acid,BASELINE,PD,566701002.0,M,C,1,Leucovorin,0,C008_408,LEUCOVORIN,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,FOLINIC ACID,200410,MD_CANCER_MEDS,01-10,200606,V03AF,Detoxifying agents for antineoplastic treatment,1,N,MAXIS-08,Folinic acid,BASELINE,SD,566701002.0,M,C,1,Leucovorin,1,C008_408,LEUCOVORIN,STABLE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,OXALIPLATIN,200410,MD_CANCER_MEDS,01-10,200606,L01XA,Platinum compounds,5,N,MAXIS-08,Oxaliplatin,BASELINE,SD,1318801001.0,M,C,1,Oxaliplatin,0,C008_408,OXALIPLATIN,STABLE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,GEMCITABINE,2004,MD_CANCER_MEDS,01-11,200503,L01BC,Pyrimidine analogues,4,N,MAXIS-08,Gemcitabine,BASELINE,SD,1215701001.0,M,C,1,Gemcitabine,0,C008_408,GEMCITABINE,STABLE DISEASE,CHEMOTHERAPY
ADJUVANT,INTERFERON,1998,MD_CANCER_MEDS,01-11,1998,L03AB,Interferons,1,N,MAXIS-08,Interferon,BASELINE,,596801001.0,A,I,1,Interferon,0,C008_408,INTERFERON,NOT APPLICABLE(IF NEOADJUVANT OR ADJUVANT REGIMEN),IMMUNOTHERAPY
METASTATIC DISEASE,INTERLEUKIN-2,2004,MD_CANCER_MEDS,01-11,200503,L03AC,Interleukins,2,N,MAXIS-08,Interleukin-2,BASELINE,SD,921302001.0,M,C,1,Interleukin-2,0,C008_408,INTERLEUKIN 2,STABLE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,SORAFENIB,20070721,MD_CANCER_MEDS,01-11,20080804,L01XE,Protein kinase inhibitors,5,N,MAXIS-08,Sorafenib,BASELINE,SD,1632501001.0,M,C,1,Sorafenib,0,C008_408,SOREFINIB,STABLE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,TEMSIROLIMUS,20081222,MD_CANCER_MEDS,01-11,20090223,L01XE,Protein kinase inhibitors,6,N,MAXIS-08,Temsirolimus,BASELINE,PD,1716501001.0,M,C,1,Temsirolimus,0,C008_408,TEMSIROLIMUS,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,,2004,MD_CANCER_MEDS,01-11,200503,L01CA,Vinca alkaloids and analogues,3,N,MAXIS-08,Vinorelbine tartrate,BASELINE,SD,988503035.0,M,C,1,Vinorelbin,0,C008_408,VINORELBIN,STABLE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,PACLITAXEL,20080904,MD_CANCER_MEDS,01-12,20090304,L01CD,Taxanes,5,N,MAXIS-08,Paclitaxel,BASELINE,SD,1116001168.0,M,C,1,Abraxane,1,C008_408,ABRAXANE,STABLE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,CYCLOPHOSPHAMIDE,20080123,MD_CANCER_MEDS,01-12,20080519,L01AA,Nitrogen mustard analogues,6,N,MAXIS-08,Cyclophosphamide,BASELINE,PD,21101004.0,M,C,1,Cytoxan,0,C008_408,CYTOXAN,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,CYCLOPHOSPHAMIDE,20090319,MD_CANCER_MEDS,01-12,200904,L01AA,Nitrogen mustard analogues,1,N,MAXIS-08,Cyclophosphamide,BASELINE,SD,21101004.0,M,C,1,Cytoxan,2,C008_408,CYTOXAN,STABLE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,DOXORUBICIN,20080318,MD_CANCER_MEDS,01-12,20080519,L01DB,Anthracyclines and related substances,3,N,MAXIS-08,Doxorubicin,BASELINE,PD,330901001.0,M,C,1,Doxorubicin,1,C008_408,DOXORUBICIN,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,DOXORUBICIN,20081029,MD_CANCER_MEDS,01-12,20090304,L01DB,Anthracyclines and related substances,6,N,MAXIS-08,Doxorubicin,BASELINE,SD,330901001.0,M,C,1,Doxorubicin,1,C008_408,DOXORUBICIN,STABLE DISEASE,CHEMOTHERAPY
ADJUVANT,LETROZOLE,200412,MD_CANCER_MEDS,01-12,20080123,L02BG,Aromatase inhibitors,2,N,MAXIS-08,Letrozole,BASELINE,,1335601001.0,A,C,1,Letrozole,0,C008_408,LETROZOLE,NOT APPLICABLE(IF NEOADJUVANT OR ADJUVANT REGIMEN),CHEMOTHERAPY
METASTATIC DISEASE,FOLINIC ACID,20071001,MD_CANCER_MEDS,01-12,200801,V03AF,Detoxifying agents for antineoplastic treatment,4,N,MAXIS-08,Folinic acid,BASELINE,PD,566701002.0,M,C,1,Leucovorin,0,C008_408,LEUCOVORIN,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,METHOTREXATE,20080123,MD_CANCER_MEDS,01-12,20080318,L01BA,Folic acid analogues,1,N,MAXIS-08,Methotrexate,BASELINE,PD,113801001.0,M,C,1,Methotrexate,1,C008_408,METHOTREXATE,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,METHOTREXATE,20090319,MD_CANCER_MEDS,01-12,200904,L01BA,Folic acid analogues,2,N,MAXIS-08,Methotrexate,BASELINE,SD,113801001.0,M,C,1,Methotrexate,2,C008_408,METHOTREXATE,STABLE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,PACLITAXEL,20080529,MD_CANCER_MEDS,01-12,20090304,L01CD,Taxanes,4,N,MAXIS-08,Paclitaxel,BASELINE,PR,1116001001.0,M,C,1,Paclitaxel,1,C008_408,PACLITAXEL,PARTIAL RESPONSE,CHEMOTHERAPY
METASTATIC DISEASE,PREDNISONE,20090319,MD_CANCER_MEDS,01-12,200904,H02AB,Glucocorticoids,4,N,MAXIS-08,Prednisone,BASELINE,PD,44701001.0,M,C,1,Prednisone,2,C008_408,PREDNISONE,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,TAMOXIFEN,19991220,MD_CANCER_MEDS,01-12,200412,L02BA,Anti-estrogens,1,N,MAXIS-08,Tamoxifen,BASELINE,SD,388701001.0,M,C,1,Tamoxifen,0,C008_408,TAMOXIFEN,STABLE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,TAMOXIFEN,20090425,MD_CANCER_MEDS,01-12,20090805,L02BA,Anti-estrogens,6,N,MAXIS-08,Tamoxifen,BASELINE,PD,388701001.0,M,C,1,Tamoxifen,2,C008_408,TAMOXIFEN,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,VINBLASTINE,20071001,MD_CANCER_MEDS,01-12,20080123,L01CA,Vinca alkaloids and analogues,3,N,MAXIS-08,Vinblastine,BASELINE,PD,115801001.0,M,C,1,Vinblastine,0,C008_408,VINBLASTINE,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,VINCRISTINE,20090319,MD_CANCER_MEDS,01-12,200904,L01CA,Vinca alkaloids and analogues,3,N,MAXIS-08,Vincristine,BASELINE,SD,78801001.0,M,C,1,Vincristine,2,C008_408,VINCRISTINE,STABLE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,CAPECITABINE,20071001,MD_CANCER_MEDS,01-12,20080123,L01BC,Pyrimidine analogues,5,N,MAXIS-08,Capecitabine,BASELINE,PD,1394301002.0,M,C,1,Xeloda,0,C008_408,XELODA,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,CAPECITABINE,20080123,MD_CANCER_MEDS,01-12,20080318,L01BC,Pyrimidine analogues,2,N,MAXIS-08,Capecitabine,BASELINE,PD,1394301002.0,M,C,1,Xeloda,1,C008_408,XELODA,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,CAPECITABINE,20090319,MD_CANCER_MEDS,01-12,200904,L01BC,Pyrimidine analogues,5,N,MAXIS-08,Capecitabine,BASELINE,SD,1394301002.0,M,C,1,Xeloda,2,C008_408,XELODA,STABLE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,CAPECITABINE,200612,MD_CANCER_MEDS,01-13,200705,L01BC,Pyrimidine analogues,5,N,MAXIS-08,Capecitabine,BASELINE,PD,1394301001.0,M,C,1,Capecitabine,0,C008_408,CAPECITABINE,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,COMBINATIONS OF ANTINEOPLASTIC AGENTS,200707,MD_CANCER_MEDS,01-13,2007,L01XY,Combinations of antineoplastic agents,1,N,MAXIS-08,Cyclophosphamide/Fluorouracil/Methotrexate,BASELINE,PD,6688901001.0,M,C,1,Cyclophosphamide w/fluorouracil/methotrexate,1,C008_408,"CYTOXAN, METHOTREXATE, FLUOROURACIL",PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,DOXORUBICIN,200712,MD_CANCER_MEDS,01-13,200812,L01DB,Anthracyclines and related substances,4,N,MAXIS-08,Doxorubicin,BASELINE,SD,330901001.0,M,C,1,Doxorubicin,1,C008_408,DOXORUBICIN,STABLE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,FULVESTRANT,200603,MD_CANCER_MEDS,01-13,200612,L02BA,Anti-estrogens,4,N,MAXIS-08,Fulvestrant,BASELINE,SD,1503001001.0,M,C,1,Fulvestrant,0,C008_408,FULVESTRANT,STABLE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,GEMCITABINE,2007,MD_CANCER_MEDS,01-13,2007,L01BC,Pyrimidine analogues,2,N,MAXIS-08,Gemcitabine,BASELINE,PD,1215701001.0,M,C,1,Gemcitabine,1,C008_408,GEMCITABINE,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,IXABEPILONE,20090605,MD_CANCER_MEDS,01-13,20090727,L01DC,Other cytotoxic antibiotics,6,N,MAXIS-08,Ixabepilone,BASELINE,PD,1676401001.0,M,C,1,Ixabepilone,1,C008_408,IXABEPILONE,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,LETROZOLE,200506,MD_CANCER_MEDS,01-13,200603,L02BG,Aromatase inhibitors,3,N,MAXIS-08,Letrozole,BASELINE,SD,1335601001.0,M,C,1,Letrozole,0,C008_408,LETROZOLE,STABLE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,PACLITAXEL,200502,MD_CANCER_MEDS,01-13,200506,L01CD,Taxanes,2,N,MAXIS-08,Paclitaxel,BASELINE,PD,1116001001.0,M,C,1,Paclitaxel,0,C008_408,PACLITAXEL,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,PACLITAXEL,2007,MD_CANCER_MEDS,01-13,200712,L01CD,Taxanes,3,N,MAXIS-08,Paclitaxel,BASELINE,PD,1116001001.0,M,C,1,Paclitaxel,1,C008_408,PACLITAXEL,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,TAMOXIFEN,1996,MD_CANCER_MEDS,01-13,2001,L02BA,Anti-estrogens,1,N,MAXIS-08,Tamoxifen,BASELINE,SD,388701001.0,M,C,1,Tamoxifen,0,C008_408,TAMOXIFEN,STABLE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,TAMOXIFEN,200812,MD_CANCER_MEDS,01-13,200903,L02BA,Anti-estrogens,5,N,MAXIS-08,Tamoxifen,BASELINE,PD,388701001.0,M,C,1,Tamoxifen,1,C008_408,TAMOXIFEN,PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,VINORELBINE,200705,MD_CANCER_MEDS,01-13,200707,L01CA,Vinca alkaloids and analogues,6,N,MAXIS-08,Vinorelbine tartrate,BASELINE,PD,988503035.0,M,C,1,Vinorelbin,0,C008_408,VINORELBINE,PROGRESSIVE DISEASE,CHEMOTHERAPY
LOCALLY ADVANCED,BEVACIZUMAB,200608,MD_CANCER_MEDS,01-14,200611,L01XC,Monoclonal antibodies,4,N,MAXIS-08,Bevacizumab,BASELINE,PD,1555201001.0,L,C,1,Bevacizumab,0,C008_408,BEVACIZUMAB,PROGRESSIVE DISEASE,CHEMOTHERAPY
LOCALLY ADVANCED,CETUXIMAB,200903,MD_CANCER_MEDS,01-14,200905,L01XC,Monoclonal antibodies,6,N,MAXIS-08,Cetuximab,BASELINE,PD,1490501001.0,L,C,1,Cetuximab,0,C008_408,CETUXIMAB,PROGRESSIVE DISEASE,CHEMOTHERAPY
LOCALLY ADVANCED,FLUOROURACIL,200606,MD_CANCER_MEDS,01-14,200712,L01BC,Pyrimidine analogues,2,N,MAXIS-08,Fluorouracil,BASELINE,SD,98801001.0,L,C,1,Fluorouracil,0,C008_408,FLUOROURACIL,STABLE DISEASE,CHEMOTHERAPY
LOCALLY ADVANCED,IRINOTECAN,200611,MD_CANCER_MEDS,01-14,200712,L01XX,Other antineoplastic agents,5,N,MAXIS-08,Irinotecan,BASELINE,SD,1280201001.0,L,C,1,Irinotecan,0,C008_408,IRINOTECAN,STABLE DISEASE,CHEMOTHERAPY
LOCALLY ADVANCED,IRINOTECAN,200903,MD_CANCER_MEDS,01-14,200905,L01XX,Other antineoplastic agents,1,N,MAXIS-08,Irinotecan,BASELINE,PD,1280201001.0,L,C,1,Irinotecan,1,C008_408,IRINOTECAN,PROGRESSIVE DISEASE,CHEMOTHERAPY
LOCALLY ADVANCED,FOLINIC ACID,200606,MD_CANCER_MEDS,01-14,200712,V03AF,Detoxifying agents for antineoplastic treatment,1,N,MAXIS-08,Folinic acid,BASELINE,SD,566701002.0,L,C,1,Leucovorin,0,C008_408,LEUCOVORIN,STABLE DISEASE,CHEMOTHERAPY
LOCALLY ADVANCED,OXALIPLATIN,200606,MD_CANCER_MEDS,01-14,200611,L01XA,Platinum compounds,3,N,MAXIS-08,Oxaliplatin,BASELINE,SD,1318801001.0,L,C,1,Oxaliplatin,0,C008_408,OXALIPLATIN,STABLE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,CETUXIMAB,200807,MD_CANCER_MEDS,01-15,20100208,L01XC,Monoclonal antibodies,1,N,MAXIS-08,Cetuximab,BASELINE,SD,1490501001.0,M,C,1,Cetuximab,0,C008_408,CETUXIMAB,STABLE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,CISPLATIN,200807,MD_CANCER_MEDS,01-15,20100208,L01XA,Platinum compounds,3,N,MAXIS-08,Cisplatin,BASELINE,SD,412101001.0,M,C,1,Cisplatin,0,C008_408,CISPLATIN,STABLE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,VINORELBINE,200807,MD_CANCER_MEDS,01-15,20100208,L01CA,Vinca alkaloids and analogues,2,N,MAXIS-08,Vinorelbine tartrate,BASELINE,SD,988503035.0,M,C,1,Vinorelbin,0,C008_408,VINORELBINE,STABLE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,PACLITAXEL,20080729,MD_CANCER_MEDS,01-16,20090922,L01CD,Taxanes,6,N,MAXIS-08,Paclitaxel,BASELINE,SD,1116001168.0,M,C,1,Abraxane,0,C008_408,ABRAXANE,STABLE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,CAPECITABINE,20041202,MD_CANCER_MEDS,01-16,20050420,L01BC,Pyrimidine analogues,4,N,MAXIS-08,Capecitabine,BASELINE,SD,1394301001.0,M,C,1,Capecitabine,0,C008_408,CAPECITABINE,STABLE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,COMBINATIONS OF ANTINEOPLASTIC AGENTS,20010424,MD_CANCER_MEDS,01-16,200106,L01XY,Combinations of antineoplastic agents,3,N,MAXIS-08,Cyclophosphamide/Fluorouracil/Methotrexate,BASELINE,PD,6688901001.0,M,C,1,Cyclophosphamide w/fluorouracil/methotrexate,0,C008_408,"CYTOXAN, METHOTREXATE, FLUOROURACIL",PROGRESSIVE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,DOXORUBICIN HYDROCHLORIDE,20100126,MD_CANCER_MEDS,01-16,20100323,L01DB,Anthracyclines and related substances,2,N,MAXIS-08,Doxorubicin hydrochloride,BASELINE,PD,330902001.0,M,C,1,Doxorubicin hydrochloride,1,C008_408,DOXORUBICIN HCL,PROGRESSIVE DISEASE,CHEMOTHERAPY
ADJUVANT,CYCLOPHOSPHAMID W/DOXORUBICIN,19980128,MD_CANCER_MEDS,01-16,19980428,L01XY,Combinations of antineoplastic agents,1,N,MAXIS-08,Cyclophosphamide/Doxorubicin,BASELINE,,1460601002.0,A,C,1,Doxorubicin w/cyclophosphamide,0,C008_408,DOXORUBICIN/CYCLOPHOSPHAMIDE,NOT APPLICABLE(IF NEOADJUVANT OR ADJUVANT REGIMEN),CHEMOTHERAPY
METASTATIC DISEASE,GEMCITABINE,20080520,MD_CANCER_MEDS,01-16,20080603,L01BC,Pyrimidine analogues,5,N,MAXIS-08,Gemcitabine,BASELINE,,1215701001.0,M,C,1,Gemcitabine,0,C008_408,GEMCITABINE,NOT APPLICABLE(IF NEOADJUVANT OR ADJUVANT REGIMEN),CHEMOTHERAPY
METASTATIC DISEASE,,20091027,MD_CANCER_MEDS,01-16,20091215,L01XY,Combinations of antineoplastic agents,1,N,MAXIS-08,Carboplatin/Gemcitabine,BASELINE,SD,6450201001.0,M,C,1,Carboplatin w/gemcitabine,1,C008_408,GEMCITABINE/CARBOPLATIN,STABLE DISEASE,CHEMOTHERAPY
METASTATIC DISEASE,VINORELBINE,20050504,MD_CANCER_MEDS,01-16,20080415,L01CA,Vinca alkaloids and analogues,3,N,MAXIS-08,Vinorelbine tartrate,BASELINE,SD,988503002.0,M,C,1,Navelbine,1,C008_408,NAVELBINE,STABLE DISEASE,CHEMOTHERAPY
ADJUVANT,PACLITAXEL,19980429,MD_CANCER_MEDS,01-16,19980701,L01CD,Taxanes,2,N,MAXIS-08,Paclitaxel,BASELINE,,1116001001.0,A,C,1,Paclitaxel,0,C008_408,PACLITAXEL,NOT APPLICABLE(IF NEOADJUVANT OR ADJUVANT REGIMEN),CHEMOTHERAPY
